PASD1 is a potential multiple myeloma-associated antigen.

PASD1 is a potential multiple myeloma-associated antigen.

Detalhes bibliográficos
Main Authors:	Sahota, S, Goonewardena, C, Cooper, C, Liggins, A, Ait-Tahar, K, Zojer, N, Stevenson, F, Banham, A, Pulford, K
Formato:	Journal article
Idioma:	English
Publicado em:	2006

Registos relacionados

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
Por: Joseph-Pietras, D, et al.
Publicado em: (2010)

Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
Por: Campbell, A, et al.
Publicado em: (2010)

PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.
Por: Cooper, C, et al.
Publicado em: (2006)

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
Por: Ait-Tahar, K, et al.
Publicado em: (2009)

Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
Por: Ait-Tahar, K, et al.
Publicado em: (2009)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
Por: Ait-Tahar, K, et al.
Publicado em: (2011)

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma
Por: Kamel Ait-Tahar, et al.
Publicado em: (2011-01-01)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
Por: Cooper, C, et al.
Publicado em: (2011)

Serologic detection of diffuse large B-cell lymphoma-associated antigens.
Por: Liggins, A, et al.
Publicado em: (2004)

Erratum: Serologic detection of diffuse large B-cell lymphoma-associated antigens (International Journal of Cancer (2004) 110 (563-569))
Por: Liggins, A, et al.
Publicado em: (2004)

A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.
Por: Liggins, A, et al.
Publicado em: (2004)

Identification of lymphoma-associated antigens using SEREX.
Por: Liggins, A, et al.
Publicado em: (2005)

Immunochemical studies of antigenic lymphoma-associated proteins.
Por: Pulford, K, et al.
Publicado em: (2002)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies
Por: Liggins, A, et al.
Publicado em: (2010)

A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.
Por: Liggins, A, et al.
Publicado em: (2010)

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
Por: Christopher D O Cooper, et al.
Publicado em: (2011-01-01)

MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
Por: Liggins, A, et al.
Publicado em: (2007)

Sp17 protein expression and major histocompatibility class I and II epitope presentation in diffuse large B cell lymphoma patients
Por: Ait-Tahar, K, et al.
Publicado em: (2017)

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy
Por: Mark van Duin, et al.
Publicado em: (2011-11-01)

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)
Por: H. Ludwig, et al.
Publicado em: (2023-05-01)

Identification of Huntingtin Interacting Protein 1 Related (HIP1R) as a Novel Lymphoma Autoantigen Using Antigen Array Profiling
Por: Wong, K, et al.
Publicado em: (2008)

Identification of Huntingtin interacting protein 1 related (HIP1R) as a novel lymphoma autoantigen using antigen array profiling
Por: Wong, K, et al.
Publicado em: (2009)

Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia.
Por: Guinn, B, et al.
Publicado em: (2005)

B and CTL responses to the ALK protein in patients with ALK-positive ALCL.
Por: Ait-Tahar, K, et al.
Publicado em: (2006)

EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE
Por: A. A. Solodovnik, et al.
Publicado em: (2018-07-01)

Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581.
Por: Banham, A, et al.
Publicado em: (2009)

Bortezomib for the treatment of multiple myeloma patients
Por: C Green, et al.
Publicado em: (2009-06-01)

Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
Por: Anja Schneller, et al.
Publicado em: (2021-04-01)

CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
Por: Ugo Testa, et al.
Publicado em: (2024-10-01)

Chimeric antigen receptor T-cell therapy for multiple myeloma
Por: Zehua Wang, et al.
Publicado em: (2022-12-01)

Chimeric antigen receptor T cell therapies for multiple myeloma
Por: Chao Wu, et al.
Publicado em: (2019-11-01)

Chimeric antigen receptor T cell therapy for multiple myeloma
Por: Kana Hasegawa, et al.
Publicado em: (2019-06-01)

Extramedullary Myeloma to the Liver Following Bispecific Antigen T-Cell Treatment for Refractory Multiple Myeloma
Por: Joelle St-Pierre, et al.
Publicado em: (2022-01-01)

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysisResearch in context
Por: Heinz Ludwig, et al.
Publicado em: (2023-04-01)

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
Por: M. Hope Robinson, et al.
Publicado em: (2023-08-01)

eNSMBL-PASD: Spearheading early autism spectrum disorder detection through advanced genomic computational frameworks utilizing ensemble learning models
Por: Ayesha Karim, et al.
Publicado em: (2025-01-01)

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
Por: Lawrie, C, et al.
Publicado em: (2008)

Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma
Por: Umair Munawar, et al.
Publicado em: (2024-04-01)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
Por: Philippe Moreau, et al.
Publicado em: (2019-12-01)

Onset of multiple myeloma with rheumatic polymyalgia
Por: E. R. Israelyan, et al.
Publicado em: (2019-12-01)